Non-viral nanosystems for systemic siRNA delivery
- PMID: 20006707
- DOI: 10.1016/j.phrs.2009.11.013
Non-viral nanosystems for systemic siRNA delivery
Abstract
To use siRNA (small interfering ribonucleic acids) for systemic administration, a delivery system is often necessary to overcome barriers between administration and the target sites. These delivery systems require different properties to be efficient. On the one hand, they have to protect siRNA from degradation and/or inactivation and, on the other hand, they have themselves to be stable in blood and possess stealth properties to avoid elimination and degradation. Active and/or passive targeting should help the delivery system to reach the desired cell type or tissue, to be internalised, and to deliver siRNA to the cytoplasm so that siRNA can act by RNA interference and inhibit protein synthesis. This review presents an overview of different non-viral delivery systems, which have been evaluated in vivo or entered in clinical trials, with a focus on their physicochemical properties in order to help the development of new and efficient siRNA delivery systems, as the therapeutic solutions of tomorrow.
Copyright 2009 Elsevier Ltd. All rights reserved.
Similar articles
-
Nonviral pulmonary delivery of siRNA.Acc Chem Res. 2012 Jul 17;45(7):961-70. doi: 10.1021/ar200110p. Epub 2011 Sep 9. Acc Chem Res. 2012. PMID: 21905687
-
Conjugates of small targeting molecules to non-viral vectors for the mediation of siRNA.Acta Biomater. 2016 May;36:21-41. doi: 10.1016/j.actbio.2016.03.048. Epub 2016 Apr 1. Acta Biomater. 2016. PMID: 27045350 Review.
-
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.Eur J Pharm Biopharm. 2011 Apr;77(3):438-49. doi: 10.1016/j.ejpb.2010.11.007. Epub 2010 Nov 18. Eur J Pharm Biopharm. 2011. PMID: 21093588 Review.
-
The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.J Control Release. 2014 Nov 10;193:113-21. doi: 10.1016/j.jconrel.2014.05.030. Epub 2014 May 24. J Control Release. 2014. PMID: 24862319 Review.
-
Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.Adv Healthc Mater. 2014 Aug;3(8):1182-93. doi: 10.1002/adhm.201300607. Epub 2014 Feb 28. Adv Healthc Mater. 2014. PMID: 24577795 Review.
Cited by
-
Insight into the relationship between the cell culture model, cell trafficking and siRNA silencing efficiency.Biochem Biophys Res Commun. 2016 Aug 19;477(2):260-5. doi: 10.1016/j.bbrc.2016.06.054. Epub 2016 Jun 24. Biochem Biophys Res Commun. 2016. PMID: 27349867 Free PMC article.
-
Efficient protection and transfection of small interfering RNA by cationic shell-crosslinked knedel-like nanoparticles.Nucleic Acid Ther. 2013 Apr;23(2):95-108. doi: 10.1089/nat.2012.0390. Nucleic Acid Ther. 2013. PMID: 23557117 Free PMC article.
-
Inorganic nanovectors for nucleic acid delivery.Drug Deliv Transl Res. 2013 Oct;3(5):446-70. doi: 10.1007/s13346-012-0116-9. Drug Deliv Transl Res. 2013. PMID: 25788353
-
Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.Int J Nanomedicine. 2020 Mar 2;15:1397-1408. doi: 10.2147/IJN.S227289. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32184594 Free PMC article.
-
Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer's.Drug Deliv. 2020 Dec;27(1):864-875. doi: 10.1080/10717544.2020.1775724. Drug Deliv. 2020. PMID: 32515999 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources